SEC Filing Summary: BioSig Technologies, Inc. (BSGM)
Business Context and Reporting Period
This Form 8-K was filed by BioSig Technologies, Inc. on May 20, 2024. The report details corporate governance actions taken by the Board of Directors regarding the appointment of independent directors to key committees. The company is incorporated in Delaware and trades on The NASDAQ Capital Market under the symbol BSGM.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and committee appointments and does not contain financial performance data.
Material Changes
The primary material change reported is the restructuring of the Board's committee assignments effective May 20, 2024. The Board appointed its independent directors to serve on the Audit, Compensation, and Nominating and Corporate Governance Committees as follows:
- Steven E. Abelman: Appointed Chairman of the Audit Committee; member of the Compensation Committee and Nominating and Corporate Governance Committee.
- Donald F. Browne: Appointed Chairman of the Compensation Committee and Chairman of the Nominating and Corporate Governance Committee; member of the Audit Committee.
- Chris Baer: Appointed member of the Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee.
Guidance, Outlook, and Management Commentary
The filing states that the appointed directors will receive compensation consistent with market practices for similarly situated companies, adhering to the Company's non-employee director compensation policy. No financial guidance, outlook, risk factors, or contingencies are disclosed in this specific report.
Key Facts for Investor Verification
- Verify the effective date of the committee appointments (May 20, 2024).
- Confirm the specific roles assigned to Steven E. Abelman, Donald F. Browne, and Chris Baer.
- Review the Company's non-employee director compensation policy to understand the remuneration structure for these appointments.
- Note that this filing contains no financial results; investors should refer to recent 10-Q or 10-K filings for financial metrics.